Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that 5-alpha reductase inhibitors had the highest association with erectile dysfunction reports among medications analyzed in the FDA's national pharmacovigilance database.

This review reports that nirmatrelvir-ritonavir has significant drug-drug interactions with many common dermatological medications, whereas molnupiravir may be an alternative therapy due to the absence of such interactions observed so far.

This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.

More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.

This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.

BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

This reference compilation details potential adverse skin reactions and other side effects associated with the antihypertensive drug Quinazil, including rare cases of skin angioedema and other dermatological reactions.

This review discusses the pharmacological properties and therapeutic potential of K+ channel opening compounds, noting their prospective use in treating cardiovascular and respiratory conditions, but reports no new results.

Minoxidil helps lower blood pressure and can also promote hair growth.

This article provides an overview of minoxidil's application as a vasodilator for severe hypertension and its topical use for treating androgenetic alopecia, detailing its effective plasma threshold levels for hair growth induction without new findings.

Scale created to measure hair loss in men and women; MK-386 reduces acne; Niaspan treats dyslipidemia; minoxidil increases heart rate.

This review provides an overview of the risks and side effects associated with common medications used to treat benign prostatic hyperplasia, highlighting the importance for clinicians and patients to discuss these aspects for informed decision-making.

This review focuses on recent advancements in understanding and treating ischemic and nonischemic priapism, but does not present new clinical results.

This review discusses the potential of nanoparticles to modify angiogenesis processes for therapeutic applications and reports no new clinical results, highlighting challenges and future prospects in treating angiogenesis-related diseases.

This study found that terazosin hydrochloride, when used with finasteride, improved prostate volume and lowered blood pressure in BPH patients with high blood pressure, although the overall treatment effect was not significantly different from controls.

This study found that both finasteride and dutasteride significantly reduced L-DOPA-induced dyskinesia in a rat model of Parkinson's disease, with dutasteride showing greater effectiveness at lower doses.

This study suggests that hesperidin may regulate pathways in hair follicle cells to help mitigate hair loss, revealing molecular mechanisms of nitric oxide donor-mediated hair follicle protection.

This review discusses hormonal control and treatment options for benign prostatic hyperplasia, highlighting similar efficacy and safety between finasteride and dutasteride, and reports no clinical results; further studies are suggested for new therapeutic agents.

This study reported that a novel vasodilator drug called TOP-M119, when delivered using a specially designed dissolving microneedle system, showed enhanced targeting of hair follicles and effectiveness in treating alopecia, demonstrated through in vitro, ex vivo, and in vivo studies involving mouse skin.

This study found that ranitidine and finasteride may have cardiovascular and renal protective effects in mice by inhibiting TMAO synthesis and improving gut microbiota composition.

Minoxidil lowers blood pressure and spreads throughout the body in normal rats.

Minoxidil helps treat severe high blood pressure.

This study reports that newly synthesized steroidal trienones exhibit higher 5α-reductase inhibitory activity than dienones in various biological models, suggesting potential use in treating androgen-dependent diseases.

In this study, the novel isoprenylcysteine analog SIG-1451 was shown to inhibit pro-inflammatory cytokine release in various cell-based assays relevant to allergic dermatitis, acting on targets such as IL-4 and IL-6 with potential anti-inflammatory benefits.

Minoxidil, when used with a diuretic and β-blocking agent, can safely lower blood pressure in most children with severe hypertension due to kidney disease, with minimal side effects.

This study observed that long-term treatment with 5ARIs in men with LUTS/BPH was linked to worsening sexual function, whereas doxazosin alone had minimal negative impact.